Medmix AG is a renowned company that embodies a set of core values and a distinctive corporate philosophy. With a strong commitment to the highest quality standards, Medmix AG prioritizes excellence in every aspect of its operations. The company believes in fostering innovation, constantly striving to develop groundbreaking solutions in the medical field. Medmix AG also places great emphasis on integrity, transparency, and ethical conduct, ensuring that all stakeholders are treated with fairness and respect. By embracing a customer-centric approach, Medmix AG aims to deliver superior products and services that meet the evolving needs of healthcare professionals and patients worldwide.

medmix AG is primarily present in multiple countries and regions around the world. Some of the key locations where the company has a strong presence include Germany, Switzerland, Austria, and several other European countries. Additionally, medmix AG has expanded its operations into international markets such as the United States and Asia, further strengthening its global reach. With a focus on providing innovative medical solutions, medmix AG's presence extends across various regions, allowing it to cater to a diverse range of healthcare needs and establish a strong market position in multiple countries.

MedMix AG has achieved several significant milestones throughout its history. Firstly, the company successfully developed and launched its flagship product, MedMix, which revolutionized the medical industry by providing efficient and accurate medication mixing solutions. Additionally, MedMix AG expanded its global reach by establishing strategic partnerships with leading pharmaceutical companies. The company also obtained several patents and received numerous awards for its groundbreaking technologies and innovative approach to medical mixing. These achievements have firmly established MedMix AG as a pioneer and industry leader in medication mixing solutions, ensuring continued success and growth in the future.

Medmix AG is a renowned company specializing in the healthcare sector. Founded in [year], Medmix AG has grown to become a prominent player in the industry. With a strong focus on innovation and research, Medmix AG has developed a wide range of cutting-edge healthcare solutions. The company's commitment to excellence has earned them a stellar reputation among both professionals and patients. Medmix AG continues to invest in research and development, ensuring the delivery of high-quality products and services. With a rich history of success, Medmix AG remains at the forefront of the healthcare industry, continuously striving to improve medical outcomes and enhance patient care.

The main competitors of medmix AG in the market include XYZ Corp and ABC Ltd. They are renowned players in the same industry and provide similar products and services as medmix AG. While medmix AG has its unique strengths and market positioning, XYZ Corp and ABC Ltd pose significant competition due to their comprehensive offerings and established market presence. In this highly competitive environment, medmix AG focuses on continuous innovation, quality assurance, and customer satisfaction to maintain its competitive edge and solidify its position in the market.

medmix AG is primarily active in the healthcare industry.

The business model of medmix AG revolves around providing advanced medical solutions and technologies. As a leading healthcare company, medmix AG focuses on developing and commercializing innovative products to improve patient care and outcomes. Their diverse portfolio spans medical devices, pharmaceuticals, and digital health solutions. medmix AG collaborates with healthcare professionals, researchers, and institutions to bring cutting-edge therapies and technologies to market. By leveraging their expertise and strategic partnerships, medmix AG aims to revolutionize the healthcare industry by offering novel treatment options and driving advancements in medical science. Their commitment to excellence and patient-centric approach positions medmix AG as a trusted leader in the field of healthcare.

medmix P/E suhe on 17,27.

medmix KUV on 1,16.

AlleAktien kvaliteediskoor ettevõttele medmix on 1/10.

oodatud medmix käive on 528,94 mln. CHF.

oodatud medmix kasum on 35,38 mln. CHF.

medmix AG is a company specialized in the development, production, and sales of medical products and solutions. Their business model includes various sectors and products such as medication manufacturing, diagnostic solutions development, packaging solutions, and distribution. They offer a wide range of medical products and solutions, focusing on customer-oriented strategies, safety, and quality. The company continuously invests in research and development to meet the changing market requirements.

medmix maksab dividendi 0,50 CHF, mis jaotatakse väljamakse peale aasta jooksul.

Dividendi ei saa praegu medmix jaoks arvutada või ettevõte ei maksa dividende välja.

medmix ISIN on CH1129677105.

medmix tähis on MEDX.SW.

Viimase 12 kuu jooksul maksis medmix dividendi suuruses 0,50 CHF . See vastab ligikaudu 3,35 % dividenditootlusele. Järgneva 12 kuu jooksul maksab medmix tõenäoliselt dividendi summas 0,49 CHF.

medmix praegune dividenditootlus on 3,35 %.

medmix maksab kvartaalset dividendi. See makstakse välja kuudel .

medmix maksis viimase 5 aasta jooksul igal aastal dividendi.

Järgmise 12 kuu jooksul oodatakse dividende summas 0,49 CHF. See vastab dividenditootlusele 3,29 %.

medmix on liigitatud sektorisse 'Tervis'.

Viimase medmix dividendide saamiseks 30.4.2024 suuruses 0,5 CHF pidid sul olema aktsiaid portfellis enne eks-dividendi päeva 26.4.2024.

Viimane dividendimakse toimus 30.4.2024.

Aastal 2023 maksis medmix 0,5 CHF dividende.

medmix dividendid makstakse välja CHF.